Gun­ning for Bio­gen’s multi­bil­lion dol­lar mar­ket, Eli Lil­ly cuts up an­oth­er batch of Alzheimer’s da­ta

Eli Lil­ly ex­ec­u­tives have their eyes set on Bio­gen’s multi­bil­lion-dol­lar Alzheimer’s mar­ket.

On Thurs­day, the In­di­anapo­lis phar­ma tried to bol­ster its case to win ac­cel­er­at­ed ap­proval for its amy­loid-clear­ing an­ti­body do­nanemab with a pair of new pre­sen­ta­tions at the Alzheimer’s As­so­ci­a­tion In­ter­na­tion­al Con­fer­ence.

Most no­tably, they ar­gued that da­ta from their Phase II tri­al showed that the more pa­tients’ amy­loid lev­els fell, the bet­ter they did cog­ni­tive­ly. There was, they wrote, a “di­rect re­la­tion­ship be­tween de­crease in amy­loid plaque and slow­ing in dis­ease pro­gres­sion rate.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.